Resistance profile of MK-5172 in interferon-containing- and interferon-free regimens

• Published in: Antiviral therapy Vol. 19; p. A46
• Main Authors: Howe, A YM, Black, S, Pak, I, Chase, R, Ingravallo, P, Ludmerer, S, Hwang, P, Gilbert, C, Bhanja, S, Shaughnessy, M, Gendrano, N N, Haber, B A, Robertson, M, Mobashery, N
• Format: Journal Article
• Language: English
• Published: 01.01.2014
• Subjects: Hepatitis C virus
• ISSN: 1359-6535

MK-5172 is a potent, broadly acting inhibitor of HCV NS3/4A protease. In treatment-naive, non-cirrhotic patients with HCV GT1 infection; (a) 12 weeks of MK-5172 100 mg + MK-8742 (NS5AI) + or -ribavirin resulted in 95% SVR12; (b) 12 weeks of MK-5172 100-800 mg + peginterferon/ribavirin (PR) followed by PR for 12/36 weeks resulted in 90% SVR24; (c) 12 weeks of MK-5172 25, 50 or 100 mg MK-5172 resulted in 54%, 84%, and 85% SVR24, respectively; (d) 12 or 24 weeks of MK-5172 100 mg + RBV resulted in 70% SVR12. In this study, we evaluate viral resistance among patients who had VF in these regimens. VF rates and resistance were distinct in patients treated with different MK-5172 regimens. RAVS with simple resistance patterns were detected in patients with viral RL, particularly among those who received interferon-based regimens.